BML Capital Management LLC Grows Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

BML Capital Management LLC boosted its stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 29.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,688,772 shares of the company’s stock after acquiring an additional 379,375 shares during the period. PMV Pharmaceuticals accounts for 1.5% of BML Capital Management LLC’s portfolio, making the stock its 14th largest holding. BML Capital Management LLC’s holdings in PMV Pharmaceuticals were worth $2,516,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of PMVP. Mirae Asset Global Investments Co. Ltd. purchased a new position in PMV Pharmaceuticals during the 1st quarter valued at approximately $26,000. Vanguard Group Inc. grew its holdings in shares of PMV Pharmaceuticals by 1.9% in the first quarter. Vanguard Group Inc. now owns 2,452,111 shares of the company’s stock valued at $4,169,000 after purchasing an additional 46,804 shares in the last quarter. Acadian Asset Management LLC increased its position in PMV Pharmaceuticals by 170.7% in the first quarter. Acadian Asset Management LLC now owns 2,080,194 shares of the company’s stock worth $3,533,000 after purchasing an additional 1,311,745 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in PMV Pharmaceuticals by 71.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 42,802 shares of the company’s stock valued at $73,000 after purchasing an additional 17,858 shares in the last quarter. Finally, Public Employees Retirement System of Ohio lifted its position in PMV Pharmaceuticals by 174.2% during the first quarter. Public Employees Retirement System of Ohio now owns 22,757 shares of the company’s stock valued at $39,000 after purchasing an additional 14,457 shares during the last quarter. 90.20% of the stock is owned by hedge funds and other institutional investors.

PMV Pharmaceuticals Stock Performance

NASDAQ PMVP traded down $0.05 during trading on Tuesday, hitting $1.71. The stock had a trading volume of 70,666 shares, compared to its average volume of 408,509. PMV Pharmaceuticals, Inc. has a one year low of $1.40 and a one year high of $3.47. The stock has a 50 day simple moving average of $1.56 and a 200 day simple moving average of $1.66. The stock has a market capitalization of $87.84 million, a price-to-earnings ratio of -1.75 and a beta of 1.49.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). On average, sell-side analysts predict that PMV Pharmaceuticals, Inc. will post -1.05 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on PMVP shares. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a report on Tuesday, August 20th. Oppenheimer upgraded PMV Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research report on Friday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $5.80.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.